These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1888 related items for PubMed ID: 22901886

  • 1. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.
    Lancet; 2012 Aug 18; 380(9842):651-9. PubMed ID: 22901886
    [Abstract] [Full Text] [Related]

  • 2. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul 18; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 18; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators.
    N Engl J Med; 2014 Sep 25; 371(13):1189-97. PubMed ID: 25199060
    [Abstract] [Full Text] [Related]

  • 8. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators.
    Lancet; 2016 Oct 29; 388(10056):2128-2141. PubMed ID: 27609406
    [Abstract] [Full Text] [Related]

  • 9. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG.
    Clin Ther; 2016 Sep 29; 38(9):2058-2070.e1. PubMed ID: 27553751
    [Abstract] [Full Text] [Related]

  • 10. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
    Lancet Respir Med; 2021 Oct 29; 9(10):1174-1184. PubMed ID: 33971168
    [Abstract] [Full Text] [Related]

  • 11. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC.
    N Engl J Med; 2017 Oct 26; 377(17):1613-1629. PubMed ID: 28893134
    [Abstract] [Full Text] [Related]

  • 12. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, Gill MA, Stokes J, Liu AH, Gruchalla RS, Cohen RT, Makhija M, Khurana Hershey GK, O'Connor GT, Pongracic JA, Sherenian MG, Rivera-Spoljaric K, Zoratti EM, Teach SJ, Kattan M, Dutmer CM, Kim H, Lamm C, Sheehan WJ, Segnitz RM, Dill-McFarland KA, Visness CM, Becker PM, Gern JE, Sorkness CA, Busse WW, Altman MC, US National Institute of Allergy and Infectious Disease's Inner City Asthma Consortium.
    Lancet; 2022 Aug 13; 400(10351):502-511. PubMed ID: 35964610
    [Abstract] [Full Text] [Related]

  • 13. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.
    N Engl J Med; 2009 Mar 05; 360(10):973-84. PubMed ID: 19264686
    [Abstract] [Full Text] [Related]

  • 14. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G.
    Lancet Respir Med; 2020 May 05; 8(5):461-474. PubMed ID: 32066536
    [Abstract] [Full Text] [Related]

  • 15. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.
    Lancet Respir Med; 2014 Nov 05; 2(11):879-890. PubMed ID: 25306557
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 17. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
    Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, Holzhauer B, Bourne M, Mistry V, Pavord ID, Mansur AH, Wardlaw AJ, Siddiqui SH, Kay RA, Brightling CE.
    Lancet Respir Med; 2016 Sep 29; 4(9):699-707. PubMed ID: 27503237
    [Abstract] [Full Text] [Related]

  • 18. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I.
    Cochrane Database Syst Rev; 2020 Dec 08; 12(12):CD013432. PubMed ID: 33295032
    [Abstract] [Full Text] [Related]

  • 19. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M.
    Clin Ther; 2019 Oct 08; 41(10):2041-2056.e5. PubMed ID: 31447130
    [Abstract] [Full Text] [Related]

  • 20. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 08; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 95.